Correspondence

Post-COVID 19 neurological syndrome: The need to define a cut-off score between the acute and post-COVID 19 phases

Dear Editor,

The COVID-19 pandemic is increasingly raising questions about the prognosis of underlying disease and the sequelae of COVID-19 disease, which depend on the phenotype developed by this condition. Post-COVID-19 syndrome has been defined as the persistence or de novo appearance of signs and/or symptoms which may or may not have been present during the acute phase of COVID-19, which are associated with target organ damage and affect the performance of activities of daily living [1–8]. So far, there is scarce and low-level (IV–V) evidence [1–8], which has discussed this concept and which highlights the importance of investigating the burden of disease it may cause, although there are studies that have shown that mortality and the risk of dying from multi-organ involvement after the acute phase of COVID-19, in the range of 30–90 days, is high [5–9].

The cut-off scores currently defined are arbitrary and have not been drawn from primary studies with specific research questions, but are drawn from some peer-reviewed reviews and quick guides, based on the time to resolution of the acute phase of COVID-19 [10]. Ståhlberg et al. [4] defined as a cut-off score in their review on post-COVID-19 tachycardia syndrome, the persistence of symptoms 4–12 weeks or more than 12 weeks after the onset of COVID-19 symptomatology [4]. However, they did not take into account those cases where the acute phase is prolonged, finding positivity in nucleic acid amplification or polymerase chain reaction tests even 20–25 days after the onset of infection, which still constitutes the acute phase of infection [9,10]. Studies have found that the tropism of SARS-Cov-2 in different organs and the susceptibility of some individuals to overactive inflammatory responses can cause the virus to persist in the tissue for a prolonged period of time, triggering minor or major pathological events in response to a stressor [11]. This is the main immunobiological argument to explain the causal relationship between the appearance of complications in the first 45–60 days, even in young people without specific risk factors [1]. Therefore, this syndrome not only constitutes a phase where symptoms such as fatigue, dyspnea or tiredness remain [4–6], but also represents a high-risk period, since it is not known in cases where there is silent target organ damage or undiagnosed personal history [7]. One of the most important phenotypes to define and investigate is the post-COVID-19 neurological syndrome, taking into account that the neurological involvement substantially compromises the functional capacity of the individual [1–3].

It has been shown that in patients with or without neurological manifestations during the acute phase of COVID-19, the cytological and biochemical study of cerebrospinal fluid, as well as neuroimaging, reveal significant alterations that represent inflammatory activity [12]. Those cases with intense neuroimmunologic reactivity may trigger clinical pictures consisting in acute myelitis, acute disseminated encephalomyelitis, acute hemorrhagic necrotizing encephalitis or acute hemorrhagic leukoencephalitis, ischemic stroke, cytotoxic lesion of the corpus callosum or mild encephalopathy reversible splenium lesion, Guillain-Barré syndrome and seizures, which can substantially reduce the functional capacity of the person affected by irreversible neurological injury, and be very evident during the post-COVID-19 phase [1, 9–13]. However, at present, where there is wide coverage of mass vaccination plans, how is post-COVID-19 syndrome defined? viral load control and lack of symptoms or under-diagnosis with other types of seasonal respiratory infections is an aspect that will hinder the accurate diagnosis of COVID-19 and post-COVID-19 syndrome in those with silent target organ damage.

It is uncertain whether there is greater activation of immune complexes and neurological inflammatory activity during the acute or post-COVID-19 phase [14], whether the negativity of molecular tests or simply the persistence or de novo appearance of symptoms long after the onset of the first symptoms, are sufficient to define a cut-off score. The importance of establishing a cut-off score will allow the design of strategies aimed at initiating neurorehabilitation at the right time, to objectively define the affection of the quality of life and the natural history of neuroinflammation, to avoid underdiagnosis and wrong therapies. We believe that this should be promoted more strongly in countries where there is a high prevalence of neurological disorders, such as neurovascular disorders or Alzheimer’s disease or other deprivations, considering the risk of complication, decompensation, disability and death. It is necessary to carry out prospective multicenter studies that massively evaluate the recording of neurological signs and/or symptoms according to the time of evolution, and obtain results that generate evidence of the highest quality.

Data statement

Data sharing is not applicable to this article as no new data were created or analysed in this study.

Ethical approval

Not applicable.

Sources of funding

None.

Author contribution

All authors equally contributed to the analysis and writing of the manuscript.

https://doi.org/10.1016/j.amsu.2021.102983

Received 24 October 2021; Accepted 28 October 2021

Available online 31 October 2021

2049-0801/© 2021 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license
Correspondence

Research registration Unique Identifying number (UIN).

1. Name of the registry: Not applicable.
2. Unique Identifying number or registration ID: Not applicable.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable.

Guarantor

Sabrina Rahman, Department of Public Health, Independent University- Bangladesh, Dhaka, Bangladesh. E-mail:

Declaration of competing interest

All authors declare that there exist no commercial or financial relationships that could, in any way, lead to a potential conflict of interest.

Provenance and peer review

Commentary, internally reviewed.

Acknowledgements

None.

References

[1] W. Camargo-Martínez, I. Lozada-Martínez, A. Escobar-Collazos, A. Navarro-Coronoado, L. Moscote-Salazar, A. Pacheco-Hernández, et al., Post-COVID 19 neurological syndrome: implications for sequelae’s treatment, J. Clin. Neurosci. 88 (2021) 219–225.

[2] M.A. González-Herazo, D.C. Silva-Muñoz, P.A. Guevara-Martínez, I.D. Lozada-Martínez, Post-COVID-19 Neurological Syndrome: a fresh challenge in neurological management, Neurol. Neurochir. Pol. 55 (6) (2021) 413–414.

[3] I.D. Lozada-Martínez, O.J. Díaz-Castillo, A.C. Pearson-Arrieta, A. Galeano-Buelvas, L.R. Moscote-Salazar, Post-COVID-19 neurological syndrome: a new risk factor that modifies the prognosis of patients with dementia, Alzheimers Dement (2021) 1–2, https://doi.org/10.1002/dad.12459.

[4] M. Ståhlberg, U. Reistam, A. Fedorowski, H. Villacorta, Y. Horichi, J. Bax, et al., Post-Covid-19 tachycardia syndrome: a distinct phenotype of post-acute covid-19 syndrome, Am. J. Med. (2021) 1–6, S0002-9343(21)00472-1, https://www.amjmed.com/article/S0002-9343(21)00472-1/fulltext, 2021.

[5] J.M. Anaya, M. Rojas, M.L. Salinas, Y. Rodríguez, G. Roa, M. Lozano, et al., Post-COVID syndrome: a case series and comprehensive review, Autoimmun. Rev. 20 (11) (2021) 1–6, https://doi.org/10.1016/j.autrev.2021.102947, https://www.sciencedirect.com/science/article/pii/S1568997221002226?via%3Dihub, 2021.

[6] D. Ayoubkhani, K. Khunti, V. Nafilyan, T. Maddox, B. Humberstone, I. Diamond, et al., SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders, Cytokine Growth Factor Rev. 58 (2021) 1–15.

[7] S. Sriwastava, M. Tandon, S. Podury, A. Prasad, S. Wen, G. Guthrie, et al., COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2, J. Neurol. (2021) 1–31.

[8] S.H. Zhou, E. Begg, R. Helbok, E. Moro, J. Sampson, V. Altamirano, et al., Global incidence of neurological manifestations among patients hospitalized with COVID-19—a report for the GCS-NeuroCOVID consortium and the ENERGY consortium, JAMA Netw Open 4 (5) (2021), e2112131.

[9] P. Orrelli, D. Ferrazzoli, L. Sebastianelli, M. Engel, R. Romanello, R. Nardone, et al., Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: insights into a challenging symptom, J. Neurol. Sci. 420 (2021) 117271.

Yurany Andrea Rodríguez-Hernández
School of Medicine, Fundación Universitaria Sanitas, Bogotá, Colombia
E-mail address: andreorodri27@gmail.com.

Francisco José Villamizar-Gómez
School of Medicine, Universidad de Santander, Bucaramanga, Colombia
E-mail address: franciscovillamizar1804@gmail.com.

Julio César Mantilla-Pardo
School of Medicine, Universidad Icesi, Cali, Colombia
E-mail address: mantilla_cesar@hotmail.com.

Ivan David Lozada-Martínez
Colombian Clinical Research Group in Neurocritical Care, Latin American Council of Neurocritical Care, Cartagena, Colombia
E-mail address: ilozadam@unicartagena.edu.co.

Khandaker Sabit Bin Razzak
Department of Public Health, American International University- Bangladesh, Dhaka, Bangladesh
E-mail address: sabitkh06@gmail.com (K.S. Bin Razzak).

* Corresponding author. Department of Public Health, American International University Bangladesh, Dhaka, Bangladesh.
E-mail address: sabit.kh06@gmail.com (K.S. Bin Razzak).